182 related articles for article (PubMed ID: 21551234)
1. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.
Lanoy E; Rosenberg PS; Fily F; Lascaux AS; Martinez V; Partisani M; Poizot-Martin I; Rouveix E; Engels EA; Costagliola D; Goedert JJ;
Blood; 2011 Jul; 118(1):44-9. PubMed ID: 21551234
[TBL] [Abstract][Full Text] [Related]
2. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma.
Kowalkowski MA; Mims MP; Amiran ES; Lulla P; Chiao EY
PLoS One; 2013; 8(10):e77409. PubMed ID: 24098586
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy.
Gotti D; Danesi M; Calabresi A; Ferraresi A; Albini L; Donato F; Castelli F; Scalzini A; Quiros-Roldan E;
AIDS Patient Care STDS; 2013 May; 27(5):259-65. PubMed ID: 23600703
[TBL] [Abstract][Full Text] [Related]
4. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes.
Bohlius J; Schmidlin K; Boué F; Fätkenheuer G; May M; Caro-Murillo AM; Mocroft A; Bonnet F; Clifford G; Paparizos V; Miro JM; Obel N; Prins M; Chêne G; Egger M;
Blood; 2011 Jun; 117(23):6100-8. PubMed ID: 21368291
[TBL] [Abstract][Full Text] [Related]
5. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.
Lacombe JM; Boue F; Grabar S; Viget N; Gazaignes S; Lascaux-Cametz AS; Pacanowski J; Partisani M; Launay O; Matheron S; Rosenthal E; Rouveix E; Tattevin P; de Truchis P; Costagliola D; Goedert JJ
AIDS; 2013 Feb; 27(4):635-43. PubMed ID: 23196937
[TBL] [Abstract][Full Text] [Related]
6. Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans.
Kowalkowski MA; Mims MA; Day RS; Du XL; Chan W; Chiao EY
Cancer Epidemiol; 2014 Aug; 38(4):386-92. PubMed ID: 24947588
[TBL] [Abstract][Full Text] [Related]
7. Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma.
Shepherd L; Ryom L; Law M; Hatleberg CI; de Wit S; Monforte AD; Battegay M; Phillips A; Bonnet F; Reiss P; Pradier C; Grulich A; Sabin C; Lundgren J; Mocroft A
J Natl Cancer Inst; 2018 Jun; 110(6):598-607. PubMed ID: 29267895
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
Mary-Krause M; Billaud E; Poizot-Martin I; Simon A; Dhiver C; Dupont C; Salmon D; Roudiere L; Costagliola D;
AIDS; 2006 Aug; 20(12):1627-35. PubMed ID: 16868444
[TBL] [Abstract][Full Text] [Related]
9. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
[TBL] [Abstract][Full Text] [Related]
10. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
11. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
[TBL] [Abstract][Full Text] [Related]
12. A declining CD4 count and diagnosis of HIV-associated Hodgkin lymphoma: do prior clinical symptoms and laboratory abnormalities aid diagnosis?
Gupta RK; Marks M; Edwards SG; Smith K; Fletcher K; Lee SM; Ramsay A; Copas AJ; Miller RF
PLoS One; 2014; 9(2):e87442. PubMed ID: 24504076
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan.
Yotsumoto M; Hagiwara S; Ajisawa A; Tanuma J; Uehira T; Nagai H; Fujikawa Y; Maeda S; Kitano K; Arima N; Uno K; Iwai T; Hongo I; Ota Y; Fukutake K; Okada S
Int J Hematol; 2012 Aug; 96(2):247-53. PubMed ID: 22752537
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors of herpes zoster in human immunodeficiency virus-positive patients initiating combination antiretroviral therapy in Taiwan.
Lee YC; Hung CC; Tsai MS; Zhang JY; Wu PY; Yang SP; Luo YZ; Chang HY; Liu WC; Sun HY; Chang SC
J Microbiol Immunol Infect; 2018 Feb; 51(1):38-44. PubMed ID: 27329131
[TBL] [Abstract][Full Text] [Related]
15. Managing HIV and Hodgkin lymphoma in the twenty-first century.
Aries J; Montoto S
Curr Hematol Malig Rep; 2014 Sep; 9(3):227-32. PubMed ID: 24906351
[TBL] [Abstract][Full Text] [Related]
16. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.
Besson C; Lancar R; Prevot S; Brice P; Meyohas MC; Marchou B; Gabarre J; Bonnet F; Goujard C; Lambotte O; Boué F; Mounier N; Partisani M; Raffi F; Costello R; Hendel-Chavez H; Algarte-Genin M; Trabelsi S; Marchand L; Raphael M; Taoufik Y; Costagliola D
Clin Infect Dis; 2015 Nov; 61(9):1469-75. PubMed ID: 26223997
[TBL] [Abstract][Full Text] [Related]
17. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV.
Guiguet M; Furco A; Tattevin P; Costagliola D; Molina JM;
HIV Med; 2007 Mar; 8(2):124-30. PubMed ID: 17352769
[TBL] [Abstract][Full Text] [Related]
18. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
[TBL] [Abstract][Full Text] [Related]
19. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
; Lanoy E; May M; Mocroft A; Phillip A; Justice A; Chêne G; Furrer H; Sterling T; Monforte AD; Force L; Gill J; Harris R; Hogg RS; Rockstroh J; Saag M; Khaykin P; de Wolf F; Sterne JA; Costagliola D
AIDS; 2009 Oct; 23(16):2199-208. PubMed ID: 19779320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
